U.S. stock night market fluctuations: WAVE Life Sciences raised $350 million, positive clinical data, stock price surged 7.64% in the night market

U.S. Stock Night Market Movements WAVE Life Sciences rose 7.64% in the night market. Based on recent key news: On December 9, WAVE Life Sciences announced a public offering worth $350 million, causing the stock price to rise. The company priced each share at $19, expanding the fundraising scale and boosting market confidence. On December 10, analysts raised their target price for WAVE Life Sciences. Citigroup increased the target price from $16 to $30, further driving up the stock price. On December 9, WAVE Life Sciences released positive Phase 1 clinical data for the WVE-007 drug, with the stock price soaring by 147%. The drug significantly improved body fat within three months, enhancing investor confidence. The biotechnology sector has recently performed strongly, with noticeable capital inflows. Stocks with High Trading Volume in the Industry Eli Lilly rose 0.54% in the night market. Based on recent key news: On December 11, Eli Lilly announced a $6 billion investment to build a factory in Alabama, increasing the production capacity of the weight-loss drug Orforglipron, which drove the stock price up. The factory is expected to start construction in 2026 and be completed in 2032, enhancing supply chain resilience. Source: Zhitong Finance On December 11, clinical trials for Eli Lilly's new weight-loss drug Retatrutide showed significant weight loss effects, with the stock price rising 1.2% in pre-market trading. The drug regulates appetite by mimicking intestinal hormones, receiving positive market feedback. Source: Zhitong Finance On December 11, Wells Fargo raised Eli Lilly's target price to $1,200, maintaining a "Buy" rating, reflecting market confidence in its future growth. Source: Gelonghui. The demand for weight-loss drugs is strong, attracting investor attention. Tilray rose 32.03% in the night market. Based on recent news: On December 11, Tilray Brands announced the launch of Amped Live Resin Liquid Diamond 1g 510 cartridges, the first active resin - liquid diamond series from the Redecan brand. The release of the new product boosted market confidence in the company's innovation capabilities, driving up the stock price. On December 12, expectations for improved regulatory conditions in the cannabis industry increased, leading to a general rise in cannabis stocks like Tilray. If reclassification progresses smoothly, the entire cannabis industry will welcome a more stable and scalable future, significantly boosting Tilray's stock price. On December 12, Tilray's cartridge products were launched in Ontario and Alberta, with plans for nationwide promotion in early 2026. The marketing of the new products further enhanced investor expectations for the company's future growth, driving up the stock price. Expectations for improved regulatory conditions in the cannabis industry have increased, boosting market confidence. Novo Nordisk rose 0.22% in the night market. Based on recent key news: On December 11, Novo Nordisk is seeking approval for a more potent version of the Wegovy injection under the U.S. priority review voucher and plans to launch an oral version early next year. Analysts believe these new products could serve as catalysts for a stock price recovery. Source: CaiLianShe On December 9, Novo Nordisk completed the acquisition of Akero Therapeutics, with a transaction value of $4.7 billion. This move may enhance the company's competitiveness in the biopharmaceutical field. Source: JieMian On December 12, Novo Nordisk launched semaglutide in India, with pricing strategies indicating the company's expansion plans in emerging markets. Source: GeLongHui Global Obesity Drug Market Size Forecast Revised Upward